Author and country | Patient group | Study type, setting and perspective | Comparators | Main results |
---|---|---|---|---|
1) Ang et al, 2001 Singapore | 115 (started) patients (6-80 years) with partial thickness (TBSA: < 40%) burns to the face excluding chemical and electrical burns. | Cost consequences, single centre study, secondary care. Perspective adopted: health care system | Silver sulfadiazine cream (C) | The median time to 75% healing was 17.0 and 20.0 days in MEBO and conventional therapy groups, respectively (Hazard Ratio: HR: 0.67; 95% CI: 0.41-1.11; p = 0.11), (similar efficacy). Bacterial infection rates were similar between the two groups (HR: 1.10; 95% CI: 0.59-2.03; p = 0.76). MEBO imparted a greater analgesic effect in the first 5 days of therapy and reduced hospital costs by 8% |
2) Atiyeh B. S. et al, Egypt, 2002 | 40 patients between (5-54 years) with superficial partial thickness burns 5-20% TBSA in adults and 5-15% TBSA in children, excluding chemical and electrical burns and patients with visual, mental or physical disabilities pregnant or lactating women as females at pregnancy risk. | Cost Benefit under a clinical prospective multi-center (five centers) study, secondary care. Perspective adopted: health care system | Silver sulphadiazine, Sofratulle Chlorhexidinetulle, Nitrofurazone, Quadriderm (betamethasone + chlorocresol+clioquinol +gentamicin+tolnaftate), Dexpanthenol, NitrofurazoneSavlon (cetrimide + chlorhexidine) Hydrogen peroxide Povidone-iodine | Patients not treated with MEBO application required statistically significant (p < 0.01) longer hospitalization. (30%) The time spent by nurses (p < 0.01) and doctors (p < 0.05), were significantly lower in MEBO as well as overall direct costs (p < 0.01.) |
3) Atiyeh B. S. et al., 2004, Saudi Arabia | 52 (started) patients (2-58 years) with a second degree TBSA burns of 5 to 35% burn (> 15% TBSA for children and > 20% for adults), excluding chemical and electrical burns | Cost consequences under a clinical prospective multi-center (14 centers) study, secondary care. Perspective adopted: health care system | Silver Sulfadiazine, Extract cepae 10%, heparin sodium 5000 iu and allantion, Panothenic acid, Chlorohexidine, Fucidic acid Bacitracin zinc and neomycin sulphate, Povidone iodine, Sofratulle. | Significant differences in favour of MEBO group concerning the reduction of 20.24% in hospitalization time (p = 0.0056), the total hospitalization cost (p = 0.025), the total time spent by physicians and nurses, the analgesic cost per day reduced by 60.8%) per course (p = 0.0135) and 55.88% per day (p = 0.0271). The other differences aren't significant. |